Search results for " Interleukin"

showing 10 items of 309 documents

Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients

1989

In this study, we investigated whether an interleukin 2 (IL-2) secretion defect by peripheral blood mononuclear cells (PBMCs) after in vitro stimulation with phytohemagglutinin (PHA-M) occurs in either newly diagnosed or long-standing type I (insulin-dependent) diabetic patients and whether it is accompanied by a dysregulation of soluble IL-2— receptor (IL-2RS) production. PBMC cultures (2.5 × 106 cells), unstimulated or stimulated with PHA-M (25 μg/ml), from 20 type I diabetic patients (10 with time since onset <3 mo and 10 with long-term diabetes of <3 yr) and 10 control subjects were studied for the production of IL-2 and IL-2RS in their respective supernatants. No differen…

AdultMaleInterleukin 2medicine.medical_specialtyTime FactorsAdolescentEndocrinology Diabetes and MetabolismStimulationPeripheral blood mononuclear cellIn vivoInternal medicineInternal MedicinemedicineHumansSecretionPhytohemagglutininsChildReceptorCells Culturedbusiness.industryLymphokineReceptors Interleukin-2In vitroDiabetes Mellitus Type 1EndocrinologySolubilityLeukocytes MononuclearInterleukin-2Femalebusinessmedicine.drug
researchProduct

Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy.

2008

AIM: To investigate gene variants in a large Italian inflammatory bowel disease (IBD) cohort, and to analyze the correlation of sub-phenotypes (including age at diagnosis) and epistatic interaction with other IBD genes. METHODS: Total of 763 patients with Crohn's disease (CD, 189 diagnosed at age < 19 years), 843 with ulcerative colitis (UC, 179 diagnosed < 19 years), 749 healthy controls, and 546 healthy parents (273 trios) were included in the study. The rs2241880 [autophagy-related 16-like 1 (ATG16L1)], rs11209026 and rs7517847 [interleukin 23 receptor (IL23R)], rs2066844, rs2066845, rs2066847 (CARD15), rs1050152 (OCTN1), and rs2631367 (OCTN2) gene variants were genotyped. RESULTS: The f…

AdultMaleInterleukin-23 receptorAdolescentGenotypeOrganic Cation Transport ProteinsIBDNod2 Signaling Adaptor ProteinAutophagy-Related Proteinsdigestive systemPolymorphism Single NucleotideInflammatory bowel diseaseYoung AdultSettore MED/38 - Pediatria Generale E SpecialisticaCrohn DiseaseIL23RClinical ResearchmedicineGenetic predispositionHumansGenetic Predisposition to DiseaseAge of OnsetYoung adultChildSolute Carrier Family 22 Member 5ReceptorAgedCrohn's diseaseSymportersbusiness.industryGastroenterologyInfantReceptors InterleukinGeneral MedicineMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisdigestive system diseasesLogistic ModelsItalyCase-Control StudiesChild PreschoolImmunologyFemaleAge of onsetCarrier Proteinsbusiness
researchProduct

High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer

2020

Abstract Background The cell surface interleukin 22 (IL-22) receptor complex is mainly expressed in epithelial and tissue cells like pancreatitis cells. Recent studies described that IL-22R was overexpressed in malignant diseases and was associated with a poor overall survival (OS). The role of IL-22RA1 gene expression in muscle invasive bladder cancer (MIBC) has not been investigated, yet. Objectives The aim of this study was to analyze the role of IL-22RA1 gene expression in patients with MIBC. Methods In a cohort of 114 patients with MIBC who underwent radical cystectomy, IL-22RA1 gene expression was analyzed with qRT-PCR and correlated with clinical parameters. Furthermore, Kaplan-Meier…

AdultMaleOncologymedicine.medical_specialtyReceptor complexUrologymedicine.medical_treatment030232 urology & nephrologyCystectomyCohort StudiesCystectomyInterleukin 2203 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineHumansNeoplasm InvasivenessAgedAged 80 and overMuscle NeoplasmsBladder cancerProportional hazards modelbusiness.industryReceptors InterleukinMiddle AgedPrognosismedicine.diseaseSurvival RateUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisCohortT-stageFemalebusinessFollow-Up StudiesUrologic Oncology: Seminars and Original Investigations
researchProduct

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central …

2021

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reac…

AdultMalePathologymedicine.medical_specialtyLymphomaBiopsyConcordanceinterleukin-10diffuse large B-cell lymphomaMutation MissenseCentral Nervous System Neoplasms03 medical and health sciencesprimary CNS lymphoma0302 clinical medicineCerebrospinal fluidhemic and lymphatic diseasesBiopsyBiomarkers TumorTaqManmedicineHumansdiffuse large B-cell lymphoma interleukin-10 interleukin-6 MYD88 L265P mutation primary CNS lymphomaProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryinterleukin-6Primary central nervous system lymphomaHematologyMiddle Agedmedicine.diseaseInterleukin-10Neoplasm ProteinsLymphomaMYD88 L265P mutationAmino Acid Substitution030220 oncology & carcinogenesisMyeloid Differentiation Factor 88FemalebusinessDiffuse large B-cell lymphoma030215 immunologyBritish Journal of Haematology
researchProduct

IL-10 and IL-10 receptor overexpression in oral giant cell lesions

2010

Objective: Central giant cell lesions (CGCL) and peripheral giant cell lesions (PGCL) occur in the jaws and contain osteoclast-like giant cells and mononuclear cells positive for the macrophage marker CD68. The participation of immune-inflammatory mechanisms has been proposed in the lesions development. As IL-10 is one of the most important anti-inflammatory cytokines and it is also an inhibitory cytokine to macrophage function and bone resorption, the purpose of the present study was to investigate its expression together with its receptor (IL-10R?) in CGCL and PGCL. Study Design: Six fragments of CGCL and seven fragments of PGCL were obtained by surgical excision. Frozen specimens were cu…

AdultMalePathologymedicine.medical_specialtymedicine.medical_treatmentBiologyPeripheral blood mononuclear cellProinflammatory cytokineYoung AdultGranuloma Giant CellmedicineHumansMacrophageReceptors Interleukin-10ChildGeneral DentistryCD68Middle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Interleukin-10Interleukin 10CytokineOtorhinolaryngologyGiant cellGranulomaUNESCO::CIENCIAS MÉDICASFemaleSurgeryMouth Diseases
researchProduct

Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis

2014

OBJECTIVE: Long-term evolution of subclinical gut inflammation to overt Crohn's disease (CD) has been described in AS patients. The aim of this study was to evaluate macrophage polarization occurring in the inflamed gut of patients with AS. METHODS: Twenty-seven HLA-B27(+) AS patients, 20 CD patients and 17 normal controls were consecutively enrolled. Classic M1 (iNOS(+)IL-10(-)), resolution phase (iNOS(+)IL-10(+)), M2 and CD14(+) macrophages were characterized by immunohistochemistry and flow cytometry. Quantitative gene expression analysis of IFN-γ, IL-4, IL-5, IL-33 and STAT6 was performed by real time PCR. RESULTS: Classic M1 macrophages were expanded in CD and AS, where resolution phas…

AdultMalePathologymedicine.medical_specialtymedicine.medical_treatmentCD14BiopsyMacrophage-activating factorMacrophage polarizationInflammationReal-Time Polymerase Chain ReactionM2 macrophageYoung AdultRheumatologyIleumMedicineMacrophageHumansPharmacology (medical)Spondylitis AnkylosingAgedbusiness.industryMacrophagesresolution phase macrophagesDNAIleitisMiddle AgedFlow CytometryImmunohistochemistryInterleukin 10Settore MED/16 - Reumatologiaankylosing spondylitiCytokinePhenotypeGene Expression RegulationM1 macrophages M2 macrophages ankylosing spondylitis gut inflammation interleukin 33 resolution phase macrophagesImmunologyCytokinesFemalegut inflammationinterleukin 33medicine.symptombusinessCD163M1 macrophage
researchProduct

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

2008

We investigated the mechanisms involved in the resistance to cell death observed in epithelial cancers. Here, we identify that primary epithelial cancer cells from colon, breast and lung carcinomas express high levels of the antiapoptotic proteins PED, cFLIP, Bcl-xL and Bcl-2. These cancer cells produced interleukin-4 (IL-4), which amplified the expression levels of these antiapoptotic proteins and prevented cell death induced upon exposure to TRAIL or other drug agents. IL-4 blockade resulted in a significant decrease in the growth rate of epithelial cancer cells and sensitized them, both in vitro and in vivo, to apoptosis induction by TRAIL and chemotherapy via downregulation of the antia…

AdultMaleProgrammed cell deathLung NeoplasmsTime Factorsapoptosis interleukin-4 cancer stem cells cancer chemiotherapy cytokinesCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinAntineoplastic AgentsApoptosisBreast NeoplasmsBiologyTNF-Related Apoptosis-Inducing LigandTumor Cells CulturedmedicineHumansAutocrine signallingMolecular BiologyInterleukin 4AgedCell ProliferationSettore MED/04 - Patologia GeneraleCell DeathDose-Response Relationship DrugCell growthCarcinomaIntracellular Signaling Peptides and ProteinsAntibodies MonoclonalInterleukin-4 Receptor alpha SubunitCorrectionCancerCell BiologyMiddle AgedPhosphoproteinsmedicine.diseaseUp-RegulationCell biologyAutocrine CommunicationProto-Oncogene Proteins c-bcl-2Drug Resistance NeoplasmApoptosisColonic NeoplasmsCancer cellFemaleInterleukin-4Interleukin-4 Cancer stem cellsSignal transductionApoptosis Regulatory ProteinsSignal Transduction
researchProduct

Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics

2015

Abstract Background Reduced innate immunity responses as well as reduced T regulatory activities characterise bronchial asthma. Objectives In this study the effect of budesonide on the expression of TLR4 and TLR2 in T regulatory lymphocyte sub-population was assessed. Methods TLR4 and TLR2 expression in total peripheral blood mononuclear cells (PBMC), in CD4+/CD25+ and in CD4+/CD25− was evaluated, by flow cytometric analysis, in mild intermittent asthmatics (n = 14) and in controls (n = 11). The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-α selected by a multiplex assay) in asthmati…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.medical_treatmentLymphocyteIn Vitro TechniquesCorticosteroids; Immunoregulation; T lymphocytes; TLR; Adult; Asthma; Budesonide; Cytokines; Female; Flow Cytometry; Glucocorticoids; Humans; In Vitro Techniques; Interleukin-10; Leukocytes Mononuclear; Male; T-Lymphocytes Regulatory; Toll-Like Receptor 2; Toll-Like Receptor 4; Young Adult; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)T-Lymphocytes RegulatoryPeripheral blood mononuclear cellYoung AdultGlucocorticoidTLRT lymphocytemedicineCorticosteroidHumansPharmacology (medical)IL-2 receptorBudesonideCytokineGlucocorticoidsIn Vitro Techniquebusiness.industryMedicine (all)Biochemistry (medical)ImmunoregulationFlow CytometryAsthmaToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4Interleukin 10TLR2Cytokinemedicine.anatomical_structureImmunologyLeukocytes MononuclearTLR4CytokinesFemalebusinessHumanmedicine.drugPulmonary Pharmacology &amp; Therapeutics
researchProduct

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn diseas…

2000

The pro-inflammatory cytokine interleukin (IL)-6 (refs. 1-5) can bind to cells lacking the IL-6 receptor (IL-6R) when it forms a complex with the soluble IL-6R (sIL-6R) (trans signaling). Here, we have assessed the contribution of this system to the increased resistance of mucosal T cells against apoptosis in Crohn disease (CD), a chronic inflammatory disease of the gastrointestinal tract. A neutralizing antibody against IL-6R suppressed established experimental colitis in various animal models of CD mediated by type 1 T-helper cells, by inducing apoptosis of lamina propria T cells. Similarly, specific neutralization of sIL-6R in vivo by a newly designed gp130-Fc fusion protein caused suppr…

AdultMaleSTAT3 Transcription FactorT-Lymphocytesmedicine.medical_treatmentT cellbcl-X ProteinApoptosisGeneral Biochemistry Genetics and Molecular BiologyMiceCrohn DiseaseAntigenAntigens CDCytokine Receptor gp130medicineAnimalsHumansInterleukin 6Mice Inbred BALB CMembrane GlycoproteinsbiologyInterleukin-6Models ImmunologicalInterleukinGeneral MedicineMiddle AgedReceptors Interleukin-6DNA-Binding ProteinsCytokinemedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisImmunologyTrans-Activatorsbiology.proteinSTAT proteinCancer researchColitis UlcerativeFemaleSignal transductionProtein BindingSignal TransductionNature Medicine
researchProduct

Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

2012

OBJECTIVE: From an immunologic standpoint, the mechanisms by which treatment with tocilizumab (TCZ), a humanized anti-interleukin-6 (anti-IL-6) receptor antibody, results in improvement in rheumatoid arthritis (RA) patients are still not fully understood. In vitro studies and studies in mouse models have demonstrated the critical role of IL-6 in Th17 cell differentiation. Th17 lymphocytes have been shown to be strongly involved in RA pathogenesis, and the purpose of this study was to investigate the effect of IL-6 blockade on the balance between Th17 cells and Treg cells in patients with active RA. METHODS: Patients with active RA for whom TCZ had been prescribed by a rheumatologist were en…

AdultMaleT cellImmunologyArthritisCell Countchemical and pharmacologic phenomenaInflammationAntibodies Monoclonal HumanizedSeverity of Illness IndexT-Lymphocytes RegulatoryArthritis Rheumatoid03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabRheumatologymedicineHumansImmunology and AllergyPharmacology (medical)IL-2 receptorInterleukin 6030304 developmental biology030203 arthritis & rheumatology0303 health sciencesbiologyInterleukin-6business.industryFOXP3hemic and immune systemsMiddle Agedmedicine.diseaseReceptors Interleukin-63. Good healthPhenotypemedicine.anatomical_structurechemistryCase-Control StudiesRheumatoid arthritisImmunologybiology.proteinTh17 CellsFemalemedicine.symptombusinessArthritis &amp; Rheumatism
researchProduct